应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NTHI NeOnc Technologies Holdings
未开盘 09-30 16:00:00 EDT
3.41
+0.11
+3.18%
盘后
3.45
+0.05
+1.32%
19:30 EDT
最高
3.47
最低
3.19
成交量
13.17万
今开
3.28
昨收
3.30
日振幅
8.48%
总市值
9,808万
流通市值
5,011万
总股本
2,881万
成交额
44.20万
换手率
0.90%
流通股本
1,472万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Neonc Technologies控股赎回6,000股A系列优先股,耗资600万美元现金,未发行普通股
美股速递 · 09-17
Neonc Technologies控股赎回6,000股A系列优先股,耗资600万美元现金,未发行普通股
NeOnc Technologies Holdings宣布完成1500万美元注册直接发行定价,纳斯达克规则下按市价面向新旧机构投资者
美股速递 · 09-09
NeOnc Technologies Holdings宣布完成1500万美元注册直接发行定价,纳斯达克规则下按市价面向新旧机构投资者
NeOnc Technologies Holdings 公布鼻内给药 Neo100 针对复发性 IDH1 突变型高级别胶质瘤的积极 2a 期顶线结果
美股速递 · 08-12
NeOnc Technologies Holdings 公布鼻内给药 Neo100 针对复发性 IDH1 突变型高级别胶质瘤的积极 2a 期顶线结果
Neonc科技公布2026年第二季度财报,并确认将于8月12日发布Neo100二期a阶段关键数据
美股速递 · 08-10
Neonc科技公布2026年第二季度财报,并确认将于8月12日发布Neo100二期a阶段关键数据
Neonc Technologies:FDA认定其CMC开发方案合理,但附加生产变更条件
美股速递 · 07-15
Neonc Technologies:FDA认定其CMC开发方案合理,但附加生产变更条件
Neonc Technologies获阿联酋IND批准推进Neo100,全球开发版图扩张,静待二期数据里程碑
美股速递 · 06-23
Neonc Technologies获阿联酋IND批准推进Neo100,全球开发版图扩张,静待二期数据里程碑
Neonc Technologies拟通过私募发行最多500万美元A系列可转换优先股 - 美国证券交易委员会文件披露
美股速递 · 06-12
Neonc Technologies拟通过私募发行最多500万美元A系列可转换优先股 - 美国证券交易委员会文件披露
Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明
美股速递 · 04-14
Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明
加载更多
公司概况
公司名称:
NeOnc Technologies Holdings
所属市场:
NASDAQ
上市日期:
--
主营业务:
Neonc Technologies Holdings, Inc.于2023年1月5日注册成立,为特拉华州公司。作为一家临床阶段的生物制药公司,该公司一直专注于建立颅内恶性肿瘤的治疗方法,即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌,如胶质母细胞瘤,和继发性脑癌,它们是通过全身其他癌症的转移扩散而来的,如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗,因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此,这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法,用于与新的候选药物联合使用。
发行价格:
--
{"stockData":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":3.405,"timestamp":1790798400000,"preClose":3.3,"halted":0,"volume":131723,"hourTrading":{"tag":"盘后","latestPrice":3.45,"preClose":3.405,"latestTime":"19:30 EDT","volume":5723,"amount":19584.2306,"timestamp":1790811003304,"change":0.045,"changeRate":0.013216,"amplitude":0.079295},"delay":0,"changeRate":0.031818181818181815,"floatShares":14715982,"shares":28805400,"eps":-2.136127,"marketStatus":"未开盘","change":0.105,"latestTime":"09-30 16:00:00 EDT","open":3.28,"high":3.47,"low":3.19,"amount":442049.5713521,"amplitude":0.084848,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.136127,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":3.3,"preHourTrading":{"tag":"盘前","latestPrice":3.4,"preClose":3.3,"latestTime":"07:38 EDT","volume":114,"amount":376.3697916,"timestamp":1790768316523,"change":0.1,"changeRate":0.030303,"amplitude":0.033333},"postHourTrading":{"tag":"盘后","latestPrice":3.45,"preClose":3.405,"latestTime":"19:30 EDT","volume":5723,"amount":19584.2306,"timestamp":1790811003304,"change":0.045,"changeRate":0.013216,"amplitude":0.079295},"volumeRatio":0.909812},"requestUrl":"/m/hq/s/NTHI","defaultTab":"news","newsList":[{"id":"1175120042","title":"Neonc Technologies控股赎回6,000股A系列优先股,耗资600万美元现金,未发行普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175120042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175120042?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:55","pubTimestamp":1789649728,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings公司近日宣布,已动用600万美元现金完成对6,000股A系列优先股的赎回操作,整个过程中未涉及任何普通股的发行。此次赎回行动,展现了公司在资本结构调整上的审慎策略,同时也凸显了其现金流的充沛与灵活性。值得留意的是,这一举措并不涉及股本稀释,对现有股东的权益未造成任何影响。市场观察人士指出,此类赎回行为通常被视为公司优化资本结构的积极信号,可能预示着管理层对公司未来前景的信心。目前,Neonc Technologies Holdings的股价表现如何,尚需进一步观察市场对这一消息的反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159616138","title":"NeOnc Technologies Holdings宣布完成1500万美元注册直接发行定价,纳斯达克规则下按市价面向新旧机构投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=1159616138","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159616138?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:01","pubTimestamp":1788955294,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings, Inc.今日正式对外宣布,其总额达1500万美元的注册直接发行已完成定价。此次发行严格遵守纳斯达克相关规则,按照市场价格进行,认购方涵盖多位新晋及现有机构投资者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168273292","title":"NeOnc Technologies Holdings 公布鼻内给药 Neo100 针对复发性 IDH1 突变型高级别胶质瘤的积极 2a 期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168273292","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168273292?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:01","pubTimestamp":1786536077,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings 宣布,其针对复发性 IDH1 突变型高级别胶质瘤患者开发的鼻内给药产品 Neo100,在 2a 期临床试验中取得了积极的顶线数据。这一结果无疑为攻克这一难治性脑瘤带来了新的希望,并进一步验证了该公司在肿瘤精准治疗领域的创新实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120133280","title":"Neonc科技公布2026年第二季度财报,并确认将于8月12日发布Neo100二期a阶段关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133280","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120133280?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:02","pubTimestamp":1786366978,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings(NTHI)今日正式披露了其2026年第二季度的财务表现。与此同时,该公司还郑重确认,其备受瞩目的Neo100二期a阶段临床试验的顶线数据,定于8月12日揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177518473","title":"Neonc Technologies:FDA认定其CMC开发方案合理,但附加生产变更条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1177518473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177518473?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:17","pubTimestamp":1784121457,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局在审阅Neonc Technologies Holdings的CMC开发方案后,认为其整体思路合理。然而,监管机构针对生产过程中的变更提出了附加条件,要求公司在实施相关调整时必须满足特定要求。CMC开发是药物获批上市的关键环节,涉及药品的生产工艺、质量控制和稳定性等核心方面。FDA的认可意味着公司在该领域的技术路径基本获得肯定,而附加条件则明确了后续优化生产中需遵循的监管框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122121747","title":"Neonc Technologies获阿联酋IND批准推进Neo100,全球开发版图扩张,静待二期数据里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1122121747","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122121747?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:05","pubTimestamp":1782219921,"startTime":"0","endTime":"0","summary":"Neonc Technologies公司宣布,其候选药物Neo100已获得阿联酋(UAE)的新药临床试验(IND)批准。这一进展标志着该公司全球开发战略的进一步拓展,为即将到来的二期临床试验数据里程碑铺平了道路。随着监管绿灯的亮起,Neo100在中东地区的临床开发路径得以开启,有望加速其作为潜在疗法的全球评估进程。公司正积极筹备后续的临床工作,市场也正密切关注其后续关键数据的发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172142321","title":"Neonc Technologies拟通过私募发行最多500万美元A系列可转换优先股 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1172142321","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172142321?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:05","pubTimestamp":1781258739,"startTime":"0","endTime":"0","summary":"根据提交至美国证券交易委员会(SEC)的文件,Neonc Technologies Holdings计划以私募方式发行最多价值500万美元的A系列可转换优先股。\n此次融资活动旨在为公司注入新的资本,以支持其业务发展计划。可转换优先股通常为投资者提供固定股息,并赋予其在特定条件下将股份转换为普通股的权利。\n该交易的具体条款,包括转换价格、股息率及最终发行规模,将在后续的正式协议中最终确定。公司通过此类非公开融资,可更为灵活地获取发展所需资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188238458","title":"Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明","url":"https://stock-news.laohu8.com/highlight/detail?id=1188238458","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188238458?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:02","pubTimestamp":1776171739,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings, Inc. (以下简称\"公司\")今日宣布,其董事长兼首席执行官近期已斥资约30万美元,在公开市场购入了公司股票(股票代码:NTHI)。此次内部人士的增持行为,彰显了公司核心管理层对未来发展的坚定信心。\n与此同时,公司管理层也针对近期公布的2025年财务业绩提供了进一步的背景说明和解读,旨在帮助投资者更全面地理解公司的财务状况与战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neonc.com","stockEarnings":[{"period":"1week","weight":0.0575},{"period":"1month","weight":-0.3107},{"period":"3month","weight":-0.2296},{"period":"6month","weight":-0.4277},{"period":"1year","weight":-0.625},{"period":"ytd","weight":-0.5883}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neonc Technologies Holdings, Inc.于2023年1月5日注册成立,为特拉华州公司。作为一家临床阶段的生物制药公司,该公司一直专注于建立颅内恶性肿瘤的治疗方法,即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌,如胶质母细胞瘤,和继发性脑癌,它们是通过全身其他癌症的转移扩散而来的,如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗,因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此,这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法,用于与新的候选药物联合使用。","exchange":"NASDAQ","name":"NeOnc Technologies Holdings","nameEN":"NeOnc Technologies Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NeOnc Technologies Holdings,NTHI,NeOnc Technologies Holdings股票,NeOnc Technologies Holdings股票老虎,NeOnc Technologies Holdings股票老虎国际,NeOnc Technologies Holdings行情,NeOnc Technologies Holdings股票行情,NeOnc Technologies Holdings股价,NeOnc Technologies Holdings股市,NeOnc Technologies Holdings股票价格,NeOnc Technologies Holdings股票交易,NeOnc Technologies Holdings股票购买,NeOnc Technologies Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}